CN1075875A - Antilipemic monascus and preparation method - Google Patents
Antilipemic monascus and preparation method Download PDFInfo
- Publication number
- CN1075875A CN1075875A CN93100737A CN93100737A CN1075875A CN 1075875 A CN1075875 A CN 1075875A CN 93100737 A CN93100737 A CN 93100737A CN 93100737 A CN93100737 A CN 93100737A CN 1075875 A CN1075875 A CN 1075875A
- Authority
- CN
- China
- Prior art keywords
- monas cuspurpureus
- cuspurpureus went
- preparation
- reducing
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
What the present invention relates to is a kind of biological medicine, especially adopts blood lipid-lowering medicine that microbial fermentation makes and preparation method thereof.Traditional Chinese medicine Monas cuspurpureus Went effect for reducing fat is minimum, and cholesterol reducing Western medicine lovastatin mevacor is the pure product of mevinolin, costs an arm and a leg, and side effect is arranged.The present invention widely collects the strong point of Chinese and western medicine, overcome its deficiency, in traditional Monas cuspurpureus Went preparation, turn out high-load blood fat reducing ingredient m evinolin first, but but make it to adopt Monas cuspurpureus Went folk prescription cholesterol reducing and triglyceride reducing and high density lipoprotein increasing-cholesterol, therapeutic effect is obvious, side effect is little, and preparation technology is simple, and cost is low.
Description
What the present invention relates to is a kind of biological medicine, especially adopts blood lipid-lowering medicine that microbial fermentation makes and preparation method thereof.
The use of Monas cuspurpureus Went is in the history in existing more than 1,000 year of China.It is documented that the invention of Monas cuspurpureus Went just has the record of " Monas cuspurpureus Went is cooked meat " about the Tang Dynasty among the five generation people Tao Guzai " clear different record " of Tang Yihou, until the modern times, Monas cuspurpureus Went still uses as food therapy agent among the people.Monas cuspurpureus Went is again a kind of common food additive, is widely used in the food-processing industries such as food, beverage.Monas cuspurpureus Went also has the spleen invigorating stomach strengthening as Chinese medicine, and the effect of blood circulation promoting and blood stasis dispelling in " Beijing's Chinese medicine processing standard " book, is listed in the local medical material in Beijing.But, the Monas cuspurpureus Went that utilizes existing method, existing strain to produce, the effect of its blood fat reducing is very little, and reason is the effective ingredient Mevinolin that does not have blood fat reducing in existing Monas cuspurpureus Went, so Monas cuspurpureus Went be used over more than 1,000 year, also never have the people that it is used as the medicine of preventing and treating hyperlipemia.
External similar fat-reducing medicament is as the lovastatin Mevacor(Lovastatin of the U.S.), only be the pure product of Mevinolin, cost an arm and a leg, side effect is arranged, only indivedual large hospitals have clinic trial.
The present invention is directed to above-mentioned Chinese medicine and Western medicine shortcoming separately, according to the characteristics of Chinese medicine Monas cuspurpureus Went blood circulation promoting and blood stasis dispelling and the lipid-reducing function of the pure product of Western medicine lovastatin (Mevacor) Mevinolin, with the combination of Chinese and Western medicine, make a kind of obvious fat-reducing effect Antilipemic monascus of little side effect again that has.
Technical solution of the present invention is in the preparation of existing Monas cuspurpureus Went, turns out the effective ingredient Mevinolin with lipid-reducing function and has another name called Lovastatin, and its chemical structural formula is:
The pure product of this Mevinolin are competitive inhibitors of rate-limiting enzyme methyl hydroxyl glutaryl coenzyme A (HMG-CoA) reductase in the cholesterol synthase system, thereby suppress the synthetic of endogenous cholesterol, reduce the cholesterol level of total plasma cholesterol, low density lipoprotein, LDL and very low density lipoprotein (VLDL).The present invention turns out the relevant composition with other of this effective ingredient in the preparation of traditional Monas cuspurpureus Went, and with other relevant composition comprehensive function in the former Monas cuspurpureus Went, make it reach the minimum fat-reducing effect of beyond thought side effect.These relevant compositions are for reducing or the collaborative minor compound that reduces plasma triglyceride and rising or collaborative high density lipoprotein increasing-cholesterol etc., they and Mevinolin blood fat reducing composition are united, can not only reduce the cholesterol level of T-CHOL in the blood plasma, low density lipoprotein, LDL and very low density lipoprotein (VLDL), triglyceride reducing and high density lipoprotein increasing-cholesterol improve its combined therapy effect effectively.
Advantage of the present invention is the strong point of widely collecting Chinese and western medicine, propose first with Monas cuspurpureus Went with the folk prescription form as the good medicine of preventing and treating hyperlipemia, overcome simultaneously in the doctor trained in Western medicine with the pure product Mevinolin that purifies and be used for shortcomings such as cost height, side effect that blood fat reducing brought be big, thereby make this medication effect obvious, side effect is little, processing technique is simple, and cost is low, economic benefit and obvious social benefit.The present invention can be used for treating hyperlipemia, can prevent and treat atherosclerosis, and to treatment coronary heart disease, the heart, cerebrovascular disease have good result, and leukemia is had certain mitigation.
Below in conjunction with embodiment, the preparation method of narration Antilipemic monascus of the present invention:
1. preparation culture fluid: murphy juice 2%, sugar 4%, yeast 0.5%;
2. add culture fluid 40-60 milliliter in each hectogram Semen Oryzae (or Semen setariae), control pH value between 4.0-8.0, high temperature sterilize;
3. connect the Monas cuspurpureus Went strain;
4.30 ℃ cultivation 2 days was cultivated 7 days for 25 ℃;
5. high temperature sterilize is dried, and pulverizes, and makes various dosage forms.
6. detection method: with the absworption peak of measurement of ultraviolet-visible spectrophotometer crude extract, in λ=230,237, the 247nm place obtains the maximum characteristic absorption peak of Mevinolin, and obtains the content of Mevinolin according to its standard working curve.
Claims (4)
1, a kind of Antilipemic monascus, what relate to is biochemistry class medicine, it is characterized in that turning out in the preparation of Chinese medicine Monas cuspurpureus Went the effective ingredient mevinolin with lipid-reducing function, and is used as the reduction high blood cholesterol drug with the folk prescription form.
2, Antilipemic monascus as claimed in claim 1 is characterized in that in this Antilipemic monascus, also includes the effective ingredient that reduces triglyceride and high density lipoprotein increasing-cholesterol etc. in the blood plasma.
3, a kind of method for preparing claim 1 Antilipemic monascus is characterized in that fermentation raw material is Semen Oryzae or Semen setariae, adds the culture fluid of being made up of murphy juice, sugar, yeast, insert the Monas cuspurpureus Went strain, under uniform temperature and time conditions, turn out the Antilipemic monascus crude drug, be made into various dosage forms again.
4, the preparation method of Antilipemic monascus as claimed in claim 3 is characterized in that:
A. culture fluid is formed: murphy juice 2%, sugar 4%, yeast 0.5%;
B. add culture fluid 40-60 milliliter in each hectogram Semen Oryzae (or Semen setariae), control pH value between 4.0-8.0, high temperature sterilize;
C. insert the Monas cuspurpureus Went strain;
D. under 30 ℃ of conditions, cultivated 1-3 days; Under 25 ℃ of conditions, cultivated 7-9 days;
E. high temperature sterilize is dried, and pulverizes;
F. make tablet, powder or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100737A CN1075875A (en) | 1993-01-01 | 1993-01-01 | Antilipemic monascus and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100737A CN1075875A (en) | 1993-01-01 | 1993-01-01 | Antilipemic monascus and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1075875A true CN1075875A (en) | 1993-09-08 |
Family
ID=4983199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100737A Pending CN1075875A (en) | 1993-01-01 | 1993-01-01 | Antilipemic monascus and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1075875A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999023996A3 (en) * | 1997-11-06 | 1999-08-19 | Univ Beijing | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| CN1061537C (en) * | 1996-09-26 | 2001-02-07 | 张茂良 | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases |
| CN1065432C (en) * | 1997-08-13 | 2001-05-09 | 北京大学 | Antilipemic monascus and its preparation |
| CN1068212C (en) * | 1997-01-31 | 2001-07-11 | 于全义 | Chinese patent drug for treating hyperlipemia |
| US7238348B2 (en) | 1996-09-30 | 2007-07-03 | Beijing Peking University Wbl Corporation Ltd. | Method of treatment of osteoporosis with compositions of red rice fermentation products |
| CN101816391A (en) * | 2010-05-27 | 2010-09-01 | 汾阳市康源发食品开发有限公司 | Monascus selenium-rich millet powder and preparation method thereof |
| CN1908156B (en) * | 2005-08-02 | 2010-12-29 | 成都地奥九泓制药厂 | Monascus novel strain and traditional Chinese medicine monascus prepared by fermenting the same |
| CN102406127A (en) * | 2011-12-09 | 2012-04-11 | 福建惠泽龙酒业有限公司 | Preparation method of lipid-lowering red yeast rice |
| EP2559433A1 (en) * | 2011-08-17 | 2013-02-20 | Sunway Biotech Co., Ltd. | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
-
1993
- 1993-01-01 CN CN93100737A patent/CN1075875A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061537C (en) * | 1996-09-26 | 2001-02-07 | 张茂良 | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases |
| US6632428B1 (en) | 1996-09-30 | 2003-10-14 | Peking University | Methods and compositions employing red rice fermentation products |
| US7238348B2 (en) | 1996-09-30 | 2007-07-03 | Beijing Peking University Wbl Corporation Ltd. | Method of treatment of osteoporosis with compositions of red rice fermentation products |
| CN1068212C (en) * | 1997-01-31 | 2001-07-11 | 于全义 | Chinese patent drug for treating hyperlipemia |
| CN1065432C (en) * | 1997-08-13 | 2001-05-09 | 北京大学 | Antilipemic monascus and its preparation |
| WO1999023996A3 (en) * | 1997-11-06 | 1999-08-19 | Univ Beijing | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| CN1908156B (en) * | 2005-08-02 | 2010-12-29 | 成都地奥九泓制药厂 | Monascus novel strain and traditional Chinese medicine monascus prepared by fermenting the same |
| CN101816391A (en) * | 2010-05-27 | 2010-09-01 | 汾阳市康源发食品开发有限公司 | Monascus selenium-rich millet powder and preparation method thereof |
| EP2559433A1 (en) * | 2011-08-17 | 2013-02-20 | Sunway Biotech Co., Ltd. | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
| CN102406127A (en) * | 2011-12-09 | 2012-04-11 | 福建惠泽龙酒业有限公司 | Preparation method of lipid-lowering red yeast rice |
| CN102406127B (en) * | 2011-12-09 | 2013-07-10 | 福建惠泽龙酒业有限公司 | Preparation method of lipid-reducing red yeast |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Emiljanowicz et al. | Kombucha from alternative raw materials–The review | |
| Dufresne et al. | Tea, Kombucha, and health: a review | |
| EP1044009B1 (en) | Methods and compositions employing red rice fermentation products | |
| Erdoğrul et al. | Review of the studies on the red yeast rice (Monascus purpureus) | |
| CN102586119B (en) | Functional monascus strain, and preparation method and application of functional highland barley monascus prepared by using functional monascus strain | |
| WO2005030938A1 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN104382164A (en) | Beverage prepared from lucid ganoderma and black tea fungus | |
| CN104304577A (en) | Biological beverage with camellia chrysantha as carrier and preparation method thereof | |
| CN1075875A (en) | Antilipemic monascus and preparation method | |
| CN102277255B (en) | Lucid ganoderma-gingko yellow wine as well as preparation method and function thereof | |
| CN104304578A (en) | Pitaya fungus tea | |
| CN101703222B (en) | Monascus-nata complex and preparation method thereof | |
| CN104273613A (en) | Mango tea fungus drink | |
| CN104273628A (en) | Biological beverage taking coix seed as raw material and preparation of biological beverage | |
| CN1272368A (en) | Selenium-enriched anka for reducing blood-fat and blood sugar | |
| CN104382129A (en) | Beverage prepared from sweet corn and black tea fungus | |
| Ayo-Lawal et al. | Evaluation of antioxidant and hypolipidaemic effects of fermented Parkia biglobosa (Jacq) seeds in tyloxapol-induced hyperlipidaemic rats | |
| CN1207902A (en) | Antilipemic monascus and its preparation | |
| CN104287044A (en) | Kiwi fruit and red tea fungus drink | |
| CN103110152A (en) | Method for preparing healthcare beverage | |
| CN107375466A (en) | A kind of medicine-food two-purpose zymotic fluid with hypolipemic function and preparation method thereof | |
| CN102613455A (en) | Xylo-oligosaccharide composition with cholesterol esterase activity inhibition function and application thereof | |
| CN1061537C (en) | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases | |
| CN103937597A (en) | Heat clearing and detoxifying peanut oil and its preparation method | |
| KR20180096023A (en) | Manufacturing method for fermentation vinegar of great burdock and its application to beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |